Sorafenib-induced erythema multiforme in metastatic renal cell carcinoma

Cutaneous and Ocular Toxicology

Volumn 28, Issue 2, 2009, Pages 90-92

  Bilaç, Cemal ^a   Müezzinoǧlu, Talha ^a   Ermertcan, Aylin Türel ^a   Kayhan, Tuba Çelebi ^a   Temeltaş, Gökhan ^a   Özütrkcan, Serap ^a   Temiz, Peyker ^a  

^a CELAL BAYAR UNIVERSITY   (Turkey)

Author keywords

Erythema multiforme; Side effect; Skin; Sorafenib

Indexed keywords

CORTICOSTEROID; PERMANGANATE POTASSIUM; SORAFENIB; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; ARM; ARTICLE; BLISTER; CANCER CHEMOTHERAPY; CASE REPORT; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ERYTHEMA MULTIFORME; EXOCYTOSIS; FOOT SOLE; HAND PALM; HUMAN; HUMAN TISSUE; IMMUNOTHERAPY; IRIS; KIDNEY CARCINOMA; LEG; MALE; METASTASIS; MULTIMODALITY CANCER THERAPY; NECK; NEPHRECTOMY; OUTPATIENT DEPARTMENT; PAPULE; PATIENT REFERRAL; SKIN BIOPSY; SKIN EXAMINATION; TREATMENT DURATION; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; KIDNEY TUMOR; MIDDLE AGED; TREATMENT OUTCOME;

SOLEIDAE;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHEMA MULTIFORME; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PYRIDINES; TREATMENT OUTCOME;

EID: 70349771027     PISSN: 15569527     EISSN: 15569535     Source Type: Journal    
DOI: 10.1080/15569520902915469     Document Type: Article

References (10)

1. Falco OB, Plewig G, Wolff HH, Burgdorf WHC. Erythematopapulo- squamous diseases. In: Dermatology. 2nd ed; Berlin: Springer-Verlag. 2000:571-647.
2. Bellmunt J, Montagut C, Albiol S, Carles J, Maroto P, Orsola A. Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents. BJU Int. 2007; 99:274-280.
3. Yang CH, Lin WC, Chuang CK, Chang YC, Pang ST, Lin YC, Kuo TT, Hsieh JJ, Chang JWC. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol. 2008; 158:592-596.
4. Porta C, Paglino C, Imarisio I, Bonomi L. Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clin Exp Med. 2007; 7:127-134.
5. Heidary N, Naik H, Burgin S. Chemotherapeutic agents and the skin: an update. J Am Acad Dermatol. 2008; 58:545-570.
6. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006; 24:2505-2512. (Pubitemid 46630627)
7. Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P. Cutaneous side effects of kinase inhibitors and blocking antibodies. Lancet Oncol. 2005; 6:491-500.
8. Robert C, Faivre S, Raymond E, Armand JP, Escudier B. Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors? Ann Intern Med. 2005; 143:313-314.
9. Lacouture ME, Desai A, Soltani K, Petronic-Rosic V, Laumann AE, Ratain MJ, Stadlert WM. Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine- kinase inhibitor. Clin Exp Dermatol. 2006; 31:783-785.
10. MacGregor JL, Silvers DN, Grossman ME, Sherman WH. Sorafenib-induced erythema multiforme. J Am Acad Dermatol. 2007; 56:527-528.